8-K: Eyenovia Secures $50 Million Investment, Pivots to Cryptocurrency Treasury Strategy with New CIO and Debt Restructuring

Eyenovia, Inc. has announced a $50 million private placement to fund a new cryptocurrency treasury strategy focused on Hyperliquid's HYPE token, alongside significant debt restructuring and key management changes.

Summary

• Eyenovia, Inc. entered into a Securities Purchase Agreement on June 17, 2025, for a private placement with institutional accredited investors, closing on June 20, 2025, raising approximately $50,000,000.
• The company issued 5,128,205 shares of Series A Non-Voting Preferred Stock and warrants to purchase 200% of the common stock issuable upon conversion of the Preferred Shares.
• Each Preferred Share is convertible into three shares of Common Stock at a conversion price of $3.25 per share.
• The Purchaser Warrants are exercisable six months and one day after issuance for five years, at an exercise price of $3.25 per share.
• Chardan Capital Markets LLC, as placement agent, received 307,692 shares of Series A Preferred Stock and warrants to purchase 1,846,153 shares of Common Stock at $3.25 per share.
• The company's pro forma outstanding Common Stock, giving effect to full conversion of Preferred Shares and exercise of all warrants, is 54,027,429 shares.
• Net proceeds from the private placement will be primarily used to build a reserve of HYPE tokens (native to Hyperliquid) and implement a HYPE staking program, as part of a new cryptocurrency treasury strategy.
• The company also intends to continue focusing on its existing business, including the development of the Gen-2 Optejet User Filled Device.
• Eyenovia amended its Loan and Security Agreement with Avenue Capital Management II, L.P. and its affiliates, extending the loan maturity date from November 1, 2025, to July 1, 2028.
• The interest rate on the loans was reduced from 12.0% to 8.0%, payable half in cash and half in kind, with an interest-only period from July 1, 2025, until January 31, 2027.
• The lenders' option to convert up to $10.0 million of loans into Common Stock was eliminated, and the company gained an option to prepay debt in part.
• In connection with the debt amendment, Eyenovia issued warrants to the lenders to purchase an aggregate of 350,000 shares of Common Stock at an exercise price of $4.00 per share.
• Hyunsu Jung was appointed Chief Investment Officer and a Board member, effective June 17, 2025, with an initial annual salary of $250,000 and equity awards including 500,000 inducement shares and 1,000,000 restricted stock units tied to market capitalization milestones ($150M and $500M).
• Three directors, Sean Ianchulev, M.D., Charles Mather IV, and Ram Palanki, Pharm. D., resigned from the Board, reconstituting it to five members.
• Michael Rowe's employment agreement was amended to allow him to retire after November 1, 2025, while retaining severance benefits.
• The Series A Preferred Stock is non-voting but grants holders certain protective rights, including requiring majority approval for significant corporate actions like mergers or adverse changes to preferred rights.
• The company expects to change its name to Hyperion DeFi and its ticker to HYPD.
• Max Fiege was appointed Strategic Advisor to support the HYPE Treasury strategy.

Sentiment

Score: 7

Explanation: The sentiment is largely positive due to the significant capital raise, favorable debt restructuring, and a bold strategic pivot that could unlock new value. However, the inherent volatility and new risks associated with the cryptocurrency strategy temper the score from being extremely positive, as does the substantial potential dilution from the new equity instruments.

Positives

• Secured significant capital infusion of approximately $50 million through a private placement, enhancing financial liquidity.
• Successfully restructured existing debt with Avenue Capital Group, extending maturity to July 1, 2028, and reducing the interest rate from 12.0% to 8.0%, improving financial terms.
• Eliminated the lenders' option to convert up to $10.0 million of loans into common stock, reducing potential dilution from this source.
• Introduced a new strategic direction by adopting a cryptocurrency treasury strategy focused on Hyperliquid's HYPE token, aiming for diversification, liquidity, and long-term capital appreciation.
• Appointed Hyunsu Jung as Chief Investment Officer and Board Member, bringing expertise in digital asset management to lead the new treasury strategy.
• The company aims to become one of the top globally active validators for Hyperliquid and the first Nasdaq-listed company to hold HYPE in its treasury, positioning itself as a pioneer in this space.
• Plans to implement a HYPE staking program and secure assets through a partnership with Anchorage Digital, potentially generating additional revenue streams.
• The company retains focus on its existing ophthalmic business, including the development of the Gen-2 Optejet User Filled Device, with anticipated FDA registration by September 2025.

Negatives

• The private placement involves significant potential dilution, with 5,128,205 shares of Series A Preferred Stock convertible into approximately 15.4 million common shares, and warrants to purchase approximately 30.8 million common shares, plus additional warrants for the placement agent and lenders.
• The shift to a cryptocurrency treasury strategy introduces new, potentially volatile, and complex risks not typically associated with a traditional ophthalmic technology company.
• The company's existing business, while still a focus, appears to be taking a secondary role to the new cryptocurrency strategy, which could impact investor perception and focus on its core competencies.
• The beneficial ownership limitations (4.99%, adjustable to 19.99%) on conversion of preferred stock and exercise of warrants may complicate the full realization of the capital raise for some investors if not managed carefully.
• The significant change in business focus and management could lead to uncertainty among existing shareholders and analysts accustomed to the company's prior direction.

Risks

• Risks associated with the viability of, and volatility inherent in, the new cryptocurrency treasury strategy, including the HYPE token.
• Uncertainties and risks related to the company's ongoing clinical trials for its ophthalmic products.
• Market conditions and the satisfaction of closing conditions for the private placement and other transactions.
• The necessity of further clinical trials for the clearance of the Optejet UFD and the timing of its FDA registration.
• Challenges in achieving anticipated sales growth for approved products.
• Reliance on third parties for the development and commercialization of the company's ophthalmic products.
• Ability to timely develop, implement, and maintain manufacturing, commercialization, and marketing capabilities and strategies for its products.
• Intellectual property risks related to its ophthalmic technology.
• Changes in legal, regulatory, legislative, and geopolitical environments in the markets where the company operates, and their impact on regulatory approval for products and product candidates.
• Competitive pressures within both the ophthalmic technology and cryptocurrency sectors.
• The company's ability to raise additional funds to maintain business operations and meet debt obligations as needed.

Future Outlook

Eyenovia plans to pivot its treasury strategy to hold Hyperliquid's HYPE token, aiming to become a top global validator and the first Nasdaq-listed company to do so, expecting long-term value creation from staking yield and on-chain utility. The company anticipates registering its Gen-2 Optejet User Filled Device with the FDA by September 2025 and will continue commercial partnering discussions for the Optejet dispenser. It also intends to change its name to Hyperion DeFi and ticker to HYPD. Future public offering proceeds will largely be directed to the new crypto treasury strategy.

Management Comments

• Michael Rowe, CEO: "We are pleased to join the growing number of companies who have adopted similar strategies for the diversification, liquidity and long-term capital appreciation potential that cryptocurrency represents."
• Michael Rowe, CEO: "Following a thorough review of all available alternatives, the Board and I have concluded that this transaction is in the best interests of our shareholders."
• Hyunsu Jung, CIO: "I am honored and excited to join the Eyenovia team to help lead this pioneering cryptocurrency treasury strategy built around what we believe to be the most robust digital asset, HYPE."
• Hyunsu Jung, CIO: "We view Hyperliquid as one of the fastest growing, highest-revenue generating blockchains in the world."
• Michael Rowe, CEO: "We are very grateful to Avenue Capital Group for their significant commitment and support of our innovative treasury strategy. We are pleased that they are positioned as a long-term partner, and we look forward to generating the sustained value creation that we anticipate from this initiative as well as the continued development and potential commercialization of our novel Optejet dispensing platform for the benefit of all shareholders."
• Max Fiege, Strategic Advisor: "It is a privilege to advise Eyenovia on the productive deployment of its HYPE treasury and I look forward to delegating Merenti Capital's own HYPE balance sheet to the Company's validator. Together, we will push the HYPE ecosystem forward."
• Max Fiege, Strategic Advisor: "Arguably no blockchain network has matched Hyperliquid's achievement: friction-free, transparent trading secured entirely on-chain. It is rare that a native token's incentives truly track the network's success. I believe HYPE is the best positioned digital asset for the future and that Eyenovia will effectively capture that value for shareholders."

Industry Context

This announcement signifies a notable strategic pivot for Eyenovia, moving beyond its traditional ophthalmic technology focus to embrace a cryptocurrency treasury strategy. This aligns with a broader, albeit still niche, trend of publicly traded companies diversifying their balance sheets with digital assets, a strategy popularized by companies like MicroStrategy with Bitcoin. By focusing on Hyperliquid's HYPE token, Eyenovia is targeting a specific Layer-1 blockchain known for its decentralized digital asset exchange and high revenue generation. This move positions Eyenovia as a pioneer among Nasdaq-listed companies in holding and actively participating in the Hyperliquid ecosystem, aiming to capitalize on the growth of decentralized finance (DeFi) and blockchain technology. The appointment of a Chief Investment Officer with a background in digital asset management underscores the seriousness of this strategic shift, indicating a commitment to actively manage and grow this new asset class alongside its existing pharmaceutical development.

Comparison to Industry Standards

• Eyenovia's adoption of a cryptocurrency treasury strategy, specifically with the HYPE token, positions it uniquely as the 'first U.S.-based publicly listed company to hold HYPE in its treasury' and aims to be 'one of the top globally active validators for Hyperliquid.' This is a novel approach compared to most publicly traded companies that typically focus on their core business and traditional financial assets.
• While not directly comparable to other pharmaceutical or ophthalmic companies, this strategy draws parallels with companies like MicroStrategy, which has famously adopted Bitcoin as its primary treasury reserve asset. However, Eyenovia's focus on a specific Layer-1 blockchain token (HYPE) and its intent to become an active validator differentiates its approach from simply holding a major cryptocurrency like Bitcoin.
• The document highlights Hyperliquid as 'one of the fastest growing, highest-revenue generating blockchains in the world,' and HYPE as the '12th-largest cryptocurrency by market capitalization as of June 2025.' This suggests Eyenovia is targeting a high-growth, albeit volatile, segment of the digital asset market, aiming to leverage its perceived strong fundamentals.
• The partnership with Anchorage Digital for securing assets indicates adherence to institutional-grade custody solutions, which is a standard practice for companies engaging with significant digital asset holdings to mitigate security risks.

Management Changes

Corporate Governance

Related Party Transactions

• The private placement was conducted with 'institutional accredited investors,' and the debt amendment was with 'Avenue Capital Management II, L.P.,' 'Avenue Venture Opportunities Fund, L.P.,' and 'Avenue Venture Opportunities Fund II, L.P.' The document states that Avenue Capital Group is now the company's 'largest common stockholder,' indicating a significant existing relationship and making the debt amendment and warrants issued to them related party transactions.
• Hyunsu Jung's appointment as CIO and Director was 'pursuant to the terms of the Purchase Agreement,' and 'Hyperion DeFi Holdings, LLC (Hyperion)' has the right to nominate his replacement and the Board Chair, indicating a close relationship between the new investors and the new management structure.

Stakeholder Impact

• **Shareholders**: Existing common shareholders face significant potential dilution from the conversion of preferred stock and exercise of warrants. However, they may benefit from the new cryptocurrency treasury strategy if it proves successful in generating long-term capital appreciation and staking yield. The debt restructuring also improves the company's financial stability.
• **Employees**: The appointment of a new Chief Investment Officer and the strategic pivot suggest a shift in company focus, potentially impacting roles and priorities for existing employees. New equity incentives for the CIO aim to align his interests with company growth.
• **Customers**: The company states it will continue to focus on its existing ophthalmic business, including the Optejet UFD, suggesting continued commitment to its product development for patients and providers.
• **Creditors**: Avenue Capital Group, as a key lender, benefits from the extended maturity date and reduced interest rate on their loans, along with warrants, indicating a strengthened relationship and potentially improved repayment prospects.
• **Investors (New)**: The institutional accredited investors in the private placement gain significant equity and warrant positions, with protective provisions for their preferred shares, and influence over the company's strategic direction and governance.

Next Steps

• The company will use net proceeds from the private placement to build a reserve of HYPE tokens and implement a HYPE staking program.
• The company will continue to focus on the development of its Gen-2 Optejet User Filled Device.
• The company anticipates registering the Gen-2 Optejet User Filled Device with the FDA by September 2025.
• The company will continue engaging in commercial partnering discussions focused on the Optejet dispenser.
• The company expects to change its name to Hyperion DeFi and its ticker symbol to HYPD.
• The company is required to prepare and file a registration statement with the SEC no later than 20 business days following June 17, 2025, to register the resale of common stock underlying the preferred shares and warrants.
• The company will include a proposal in the proxy statement for its 2025 annual meeting of stockholders to increase the number of shares of Common Stock reserved for issuance under its equity compensation plan by 5,172,934 shares.
• For future public offerings, the company agrees to deposit not less than 80% of net proceeds (less operating budget needs) into the Funding Accounts for the Treasury Strategy, unless consented otherwise by a majority of Preferred holders.
• The restructured loans will have an interest-only period until January 31, 2027, followed by monthly principal and interest payments until July 1, 2028.

Key Dates

Recommendation

Keywords

Eyenovia, Hyperliquid, HYPE token, Cryptocurrency treasury strategy, Private placement, SEC filing, 8-K, Debt restructuring, Corporate governance, Optejet, Ophthalmic technology, Biotechnology, Digital assets, Preferred stock, Warrants, Nasdaq, HYPD, Hyperion DeFi